Related Experiment Videos
Programmed cell death in human breast cancer cells
D E McCloskey1, D K Armstrong, C Jackisch
1Johns Hopkins Oncology Center, Baltimore, Maryland 21231, USA.
Abstract:
The need for improved systemic therapy for breast cancer is great. Cancer growth represents an imbalance between cell proliferation and cell death: thus, effective anti-cancer therapies may act to decrease cell proliferation or increase cell death, or both. This chapter delineates the role of the programmed cell death process in maintaining homeostasis in normal mammary tissues. The preservation of such death pathways in malignant mammary cells and the ability of chemotherapeutic agents to initiate the programmed cell death process in these cells is reviewed. Finally, ongoing research exploring new ways to take advantage of these death pathways in the clinical setting is examined.
Insights
Targeting programmed cell death pathways offers a promising strategy for improving systemic therapy in breast cancer. Research explores harnessing these natural cell death mechanisms to combat cancer growth effectively.
Area of Science:
- Oncology
- Cell Biology
- Cancer Therapeutics
Background:
- Breast cancer treatment necessitates novel systemic therapies due to complex growth dynamics.
- Cancer progression involves an imbalance between cellular proliferation and programmed cell death.
- Understanding cell death pathways is crucial for developing effective anti-cancer strategies.
Purpose of the Study:
- To review the role of programmed cell death in normal mammary tissue homeostasis.
- To examine the preservation and exploitation of cell death pathways in breast cancer.
- To explore novel clinical applications targeting programmed cell death.
Main Methods:
- Literature review focusing on programmed cell death mechanisms in mammary tissues.
- Analysis of chemotherapeutic agent efficacy in inducing programmed cell death in cancer cells.
- Examination of current research on clinical strategies targeting cell death pathways.
Main Results:
- Programmed cell death is vital for maintaining normal mammary tissue balance.
- Malignant mammary cells often retain susceptibility to programmed cell death induction.
- Chemotherapeutic agents can initiate programmed cell death in breast cancer cells.
Conclusions:
- Targeting programmed cell death pathways represents a significant therapeutic avenue for breast cancer.
- Further research into clinical applications of these pathways holds promise for improved patient outcomes.
- Harnessing cell death mechanisms offers a strategy to re-sensitize resistant cancer cells.